Help
RSS
API
Feed
Maltego
Contact
Domain > ir.bioatla.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-10-29
104.119.188.185
(
ClassC
)
2024-10-08
23.222.27.176
(
ClassC
)
2026-01-29
23.216.147.205
(
ClassC
)
Port 443
HTTP/1.1 200 OKContent-Language: enContent-Type: text/html; charsetUTF-8ETag: 1769716154Expect-CT: max-age0, report-uri/report-expect-ct-violationFeature-Policy: accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr noneFrom-Origin: sameLast-Modified: Thu, 29 Jan 2026 19:49:14 GMTReferrer-Policy: no-referrer-when-downgradeStrict-Transport-Security: max-age31536000X-Age: 63X-Cache-Hits: 1X-Content-Type-Options: nosniffX-Drupal-Dynamic-Cache: UNCACHEABLE (poor cacheability)X-Frame-Options: SAMEORIGINX-Request-ID: v-96dd675c-fd4b-11f0-9ed9-bbd741c69043X-XSS-Protection: 1; modeblockCache-Control: public, max-age0, s-maxage2700Expires: Thu, 29 Jan 2026 19:50:18 GMTDate: Thu, 29 Jan 2026 19:50:18 GMTContent-Length: 43836Connection: keep-alive !DOCTYPE html>html langen dirltr prefixog: https://ogp.me/ns#> head> meta charsetutf-8 />meta namedescription contentThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. />link relcanonical hrefhttps://ir.bioatla.com/investor-relations/ />link relshortlink hrefhttps://bioatla.gcs-web.com/ />meta namereferrer contentno-referrer />meta propertyog:site_name contentBioAtla, Inc />meta propertyog:type contentwebsite />meta propertyog:url contenthttps://ir.bioatla.com/investor-relations />meta propertyog:title contentInvestor Relations | BioAtla, Inc />meta propertyog:description contentThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. />meta nameGenerator contentDrupal 10 (https://www.drupal.org) />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />link relicon href/sites/g/files/knoqqb64926/files/favicon.ico typeimage/vnd.microsoft.icon />link relalternate hreflangen hrefhttps://ir.bioatla.com/ /> title>Investor Relations | BioAtla, Inc/title> link relstylesheet mediaall href/sites/g/files/knoqqb64926/files/css/css_r2ur90kDl_podI-60DabpUtlIEFSuPxV5WX-6pN3Wrw.css?delta0&languageen&themenir_pid4199&includeeJyNj0EKwzAMBD8UYgq95DVCtkUqYktBVlL6-zrJpT0UehHLspJmkxqFbNuKZcyMRedB2CBio3AITirt23LVEtFOs6It5JDREWLRtAQULK_mYOgsc98ySA80_yvewDEW-pGthAJGSWsl6T6rfNxecb74DjF2bCdxaC9JHUKELuCV8_02TUF3MuNMQ-vfqYaj3bAzPVs451g1b4XeoZBwuQ />link relstylesheet mediaall href/sites/g/files/knoqqb64926/files/css/css_t_30QjiSBBeQEQF4TbnkjRY1gpblYN-UcvXqi9V-2n8.css?delta1&languageen&themenir_pid4199&includeeJyNj0EKwzAMBD8UYgq95DVCtkUqYktBVlL6-zrJpT0UehHLspJmkxqFbNuKZcyMRedB2CBio3AITirt23LVEtFOs6It5JDREWLRtAQULK_mYOgsc98ySA80_yvewDEW-pGthAJGSWsl6T6rfNxecb74DjF2bCdxaC9JHUKELuCV8_02TUF3MuNMQ-vfqYaj3bAzPVs451g1b4XeoZBwuQ />link relstylesheet mediaall href//fonts.googleapis.com/css2?familyRoboto:ital,wght@0,100;0,300;0,400;0,500;0,700;1,300;1,400;1,500&displayswap />link relstylesheet mediaall href//fonts.googleapis.com/css2?familyRoboto+Condensed:wght@300;400;700&displayswap />link relstylesheet mediaall href/sites/g/files/knoqqb64926/files/css/css_xf2H_M0aP_gGs1E6HJb9tQUGJ8wuVflxmr2TGw--lTU.css?delta4&languageen&themenir_pid4199&includeeJyNj0EKwzAMBD8UYgq95DVCtkUqYktBVlL6-zrJpT0UehHLspJmkxqFbNuKZcyMRedB2CBio3AITirt23LVEtFOs6It5JDREWLRtAQULK_mYOgsc98ySA80_yvewDEW-pGthAJGSWsl6T6rfNxecb74DjF2bCdxaC9JHUKELuCV8_02TUF3MuNMQ-vfqYaj3bAzPVs451g1b4XeoZBwuQ />link relstylesheet mediaprint href/sites/g/files/knoqqb64926/files/css/css_Dk1hkrCuVzD5u5FTP3_-kz3auQKlQ0ItfoAkJkOyntg.css?delta5&languageen&themenir_pid4199&includeeJyNj0EKwzAMBD8UYgq95DVCtkUqYktBVlL6-zrJpT0UehHLspJmkxqFbNuKZcyMRedB2CBio3AITirt23LVEtFOs6It5JDREWLRtAQULK_mYOgsc98ySA80_yvewDEW-pGthAJGSWsl6T6rfNxecb74DjF2bCdxaC9JHUKELuCV8_02TUF3MuNMQ-vfqYaj3bAzPVs451g1b4XeoZBwuQ /> script src/core/assets/vendor/modernizr/modernizr.min.js?v3.11.7>/script>script src/sites/g/files/knoqqb64926/files/js/js_XhNHlYdVCldBGa-sVJxdebRfKLpuFOJOIlfzfKkVAJE.js?scopeheader&delta1&languageen&themenir_pid4199&includeeJyVUFtqAzEMvFBYE-hPvnOCkgMI2RKJs1prkbVtcvts7EIeFEox2DPjkTxWyQZYUK6eUw3lmQ1IGhkEl5JOm_KncTalZotYuTlcVSJaE9PIlF0NCH1dUbiGB2yWCW1kbwaIomkMv6pD0mnCQv-qqb7un4s697JFPE9rIgyvtN3OeOwfuIMBz3gBJIIkWCugsHkPPGf62O52Qb_YLFNv3V6CdELz8MZ7iv0dHvwquRxbxTfHmp2h6DpN7sN904af8wbmj6p5>/script> /head> body classbody-sidebars-none nir-node nir-node--type-nir-landing-page nir-node--5806 path-frontpage page-node-type-nir-landing-page> div idskip> a classvisually-hidden focusable skip-link href#main-menu> Skip to main navigation /a> /div> div classdialog-off-canvas-main-canvas data-off-canvas-main-canvas> div idpreloader> div classpreloader-container> h4 classback-logo>img classlogo src/sites/g/files/knoqqb64926/themes/site/nir_pid4199/dist/images/logo-footer.svg altBioAtla, Inc logo>/h4> !-- h4 classpreload-logo fadeInLeft animated-slow>Investor Relations/h4> --> img src/sites/g/files/knoqqb64926/themes/site/nir_pid4199/dist/images/preload.gif classpreload-gif altpreloader> /div>/div>div idtop>/div>header> div classtop-bar sticky is-at-top is-stuck> div classrow> div classcolumn large-12> div classtop-bar-left> a hrefhttps://www.bioatla.com/> img classlogo src/sites/g/files/knoqqb64926/themes/site/nir_pid4199/dist/images/logo-footer.svg altBioAtla, Inc logo> /a> /div> div classtop-bar-right> div classtitle-bar data-responsive-togglemain-menu data-hide-forlarge> button classmenu-icon typebutton data-togglemain-menu aria-labelMenu icon>/button> !-- div classtitle-bar-title>Menu/div> --> /div> div class idmain-menu> ul classmenu vertical large-horizontal large-text-left data-responsive-menudrilldown large-dropdown rolenavigation> li> a href/ rolelink>Overview/a> /li> li classhas-submenu> a href/news-and-events/news-releases rolelink>News & Events/a> ul classsubmenu menu vertical data-submenu> li classside-menu__item> a href/news-and-events/news-releases rolelink>News Releases/a> /li> li classside-menu__item> a href/news-and-events/events-and-presentations rolelink>Events and Presentations/a> /li> /ul> /li> li classhas-submenu> a href/corporate-governance/governance-overview rolelink>Governance/a> ul classsubmenu menu vertical data-submenu> li classside-menu__item> a href/corporate-governance/governance-overview rolelink>Governance Overview/a> /li> li classside-menu__item> a hrefhttps://www.bioatla.com/about/#board-of-directors rolelink>Board of Directors/a> /li> li classside-menu__item> a hrefhttps://www.bioatla.com/about/#team rolelink>Management/a> /li> li classside-menu__item> a href/corporate-governance/committee-composition rolelink>Committee Composition/a> /li> /ul> /li> li classhas-submenu> a href/financial-information/sec-filings rolelink>Financials/a> ul classsubmenu menu vertical data-submenu> li classside-menu__item> a href/financial-information/sec-filings rolelink>SEC Filings/a> /li> li classside-menu__item> a href/financial-information/quarterly-results rolelink>Quarterly Results/a> /li> li classside-menu__item> a href/financial-information/annual-reports rolelink>Annual Reports/a> /li> /ul> /li> li classhas-submenu> a href/stock-information rolelink>Stock/a> ul classsubmenu menu vertical data-submenu> li classside-menu__item> a href/stock-information rolelink>Stock Quote & Chart/a> /li> li classside-menu__item> a href/stock-information/historic-price-lookup rolelink>Historic Price Lookup/a> /li> li classside-menu__item> a href/stock-information/investment-calculator rolelink>Investment Calculator/a> /li> li classside-menu__item> a href/stock-information/analyst-coverage rolelink>Analyst Coverage/a> /li> /ul> /li> li classhas-submenu> a href/resources/investor-faqs rolelink>Resources/a> ul classsubmenu menu vertical data-submenu> li classside-menu__item> a href/resources/investor-faqs rolelink>Investor FAQs/a> /li> li classside-menu__item> a href/resources/email-alerts rolelink>Email Alerts/a> /li> li classside-menu__item> a href/resources/contact-ir rolelink>Contact IR/a> /li> /ul> /li> /ul> /ul> /div> /div> /div> /div> /div>/header> section classbanner idhome-pattern rolecomplementary> div classparallax-overlay>/div> div classrow carousel> div classowl-carousel idhero-carousel> div idblock-widgetnewsv2-2 classblock--tw-hero-news block--nir-news__widget block--nir-news__widget--5806 block--hero--nir-news__widget block--hero--nir-news__widget--5806 block--b95de7e3-9d6b-4153-8e14-d54c0c8e913e block--b95de7e3-9d6b-4153-8e14-d54c0c8e913e--5806 block block-nir-news block-nir-news__widget item> div classnir-widget> div classnir-widget--content> article classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted> h2 classh1 text-white> span class>BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)/span> /h2> div classnir-widget--field nir-widget--news--date-time> p classlead>December 31, 2025/p> /div> a classbutton href/news-releases/news-release-details/bioatla-and-gatc-health-announce-40-million-special-purpose>Read More/a> /article> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div>div idblock-widgetnewsv2 classblock--tw-hero-news block--nir-news__widget block--nir-news__widget--5806 block--hero--nir-news__widget block--hero--nir-news__widget--5806 block--507dd32f-d14c-4c4b-ad6f-5231a303dd1c block--507dd32f-d14c-4c4b-ad6f-5231a303dd1c--5806 block block-nir-news block-nir-news__widget item> div classnir-widget> div classnir-widget--content> article classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted> h2 classh1 text-white> span class>BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing/span> /h2> div classnir-widget--field nir-widget--news--date-time> p classlead>November 21, 2025/p> /div> a classbutton href/news-releases/news-release-details/bioatla-enters-agreements-225-million-flexible-financing>Read More/a> /article> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div>div idblock-widgetnewsv2-3 classblock--tw-hero-news block--nir-news__widget block--nir-news__widget--5806 block--hero--nir-news__widget block--hero--nir-news__widget--5806 block--53010da8-ed32-48b2-a43c-a5e59e9dabe9 block--53010da8-ed32-48b2-a43c-a5e59e9dabe9--5806 block block-nir-news block-nir-news__widget item> div classnir-widget> div classnir-widget--content> article classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted> h2 classh1 text-white> span class>BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress/span> /h2> div classnir-widget--field nir-widget--news--date-time> p classlead>November 13, 2025/p> /div> a classbutton href/news-releases/news-release-details/bioatla-reports-third-quarter-2025-financial-results-and>Read More/a> /article> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div> /div> /div> div classhome-bottom> div classrow text-center> div classmove> a href#profile classfa fa-chevron-down aria-labeldown to content>/a> /div> /div> /div> /section>div rolemain> div idndq-content classndq-5806> div classregion region-content> div data-drupal-messages-fallback classhidden>/div>div idblock-nir-pid4199-content classblock--system-main-block block--system-main-block--5806 block--content--system-main-block block--content--system-main-block--5806 block--8b0c596c-3820-4e60-ab72-9d00075cd672 block--8b0c596c-3820-4e60-ab72-9d00075cd672--5806 block block-system block-system-main-block> article classnode node--type-nir_landing_page node--view-mode-full clearfix> div> div classpanel-display sutro-double clearfix > div classcontainer-fluid> section idprofile classbg_w text-center > div classrow revealOnScroll-fadeInUp radix-layouts-header> div classpanel-panel-inner columns large-12> div classblock-region-header>div classblock-content--nir-global-block block-content--nir-global-block--6116 block--block-contentf390be37-9ad7-4a7e-a354-7aad647bf74c block--block-contentf390be37-9ad7-4a7e-a354-7aad647bf74c--5806 block--header--block-content--f390be37-9ad7-4a7e-a354-7aad647bf74c block--header--block-content--f390be37-9ad7-4a7e-a354-7aad647bf74c--5806 block--62a3f554-e81b-4368-97e5-6d45e942029b block--62a3f554-e81b-4368-97e5-6d45e942029b--5806 block block-block-content block-block-contentf390be37-9ad7-4a7e-a354-7aad647bf74c> h2>Overview/h2> div classfield field--name-field-nir-global-block-node field--type-entity-reference field--label-hidden field__item> div classfield field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item>BioAtla is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics, or CABs, enable us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our approach is to identify the necessary targeting and potency required for cancer cell destruction, while aiming to eliminate or greatly reduce on-target, off-tumor toxicity—one of the fundamental challenges of existing cancer therapies. We have initiated Phase 2 trials for our two latest stage ADC product candidates in multiple high unmet need cancer indications, including sarcoma, I/O failure NSCLC and melanoma. We are also supporting investigator-initiated trials in platinum-resistant ovarian cancer. Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to ensure patients’ improved quality of life./div> /div> /div>/div> /div> /div> /section> section idnews class> div classrow radix-layouts-middle> div classlarge-12 columns> div classpanel-panel-inner> div classblock-region-middle>div classblock--nir-news__widget block--nir-news__widget--5806 block--middle--nir-news__widget block--middle--nir-news__widget--5806 block--3af540cd-fdfd-4b45-b154-d5c0bb32e60c block--3af540cd-fdfd-4b45-b154-d5c0bb32e60c--5806 block block-nir-news block-nir-news__widget> div classnir-widget> h2>Latest News/h2> div classnir-widget--content> ul classblock-grid small-block-grid-1 medium-block-grid-1 large-block-grid-3 text-center flexy> li classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted overlay-fade-in revealOnScroll-fadeInUp> a href/news-releases/news-release-details/bioatla-and-gatc-health-announce-40-million-special-purpose> div classh6>Recent Release/div> i classfa fa-newspaper-o fa-2x>/i> div classh4>BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)/div> p> 12/31/25 /p> p classmobile button>Read Release/p> span classoverlay-content>div classcta>Read Release i classfa fa-chevron-right>/i>/div>/span> /a>/li>li classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted overlay-fade-in revealOnScroll-fadeInUp> a href/news-releases/news-release-details/bioatla-enters-agreements-225-million-flexible-financing> div classh6>Recent Release/div> i classfa fa-newspaper-o fa-2x>/i> div classh4>BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing/div> p> 11/21/25 /p> p classmobile button>Read Release/p> span classoverlay-content>div classcta>Read Release i classfa fa-chevron-right>/i>/div>/span> /a>/li>li classclearfix node node--nir-news--nir-widget-list node--type-nir-news node--view-mode-nir-widget-list node--promoted overlay-fade-in revealOnScroll-fadeInUp> a href/news-releases/news-release-details/bioatla-reports-third-quarter-2025-financial-results-and> div classh6>Recent Release/div> i classfa fa-newspaper-o fa-2x>/i> div classh4>BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress/div> p> 11/13/25 /p> p classmobile button>Read Release/p> span classoverlay-content>div classcta>Read Release i classfa fa-chevron-right>/i>/div>/span> /a>/li> /ul> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div>div classblock-content--nir-lp-block block-content--nir-lp-block--7026 block--block-contente0de305d-7984-4616-8ca6-ae01b3bf121d block--block-contente0de305d-7984-4616-8ca6-ae01b3bf121d--5806 block--middle--block-content--e0de305d-7984-4616-8ca6-ae01b3bf121d block--middle--block-content--e0de305d-7984-4616-8ca6-ae01b3bf121d--5806 block--fe1cc225-77be-43ac-a87d-26eea8934eb0 block--fe1cc225-77be-43ac-a87d-26eea8934eb0--5806 block block-block-content block-block-contente0de305d-7984-4616-8ca6-ae01b3bf121d> div classfield field--name-field-nir-lp-block-node field--type-entity-reference field--label-hidden field__item> div classfield field--name-field-nir-lp-block-body field--type-text-long field--label-hidden field__item>p classtext-center>a classbutton href/news-and-events/news-releases>View More/a>/p>/div> /div> /div>/div> /div> /div> /div> /section> section idquicklinks> div classrow> div classcolumns large-6 radix-layouts-secondcolumn1 panel-panel> div classpanel-panel-inner> div classblock-region-secondcolumn1>div classviews-element-container block--views-blockwidget-bundled-content-block-1 block--views-blockwidget-bundled-content-block-1--5806 block--secondcolumn1--views-block--widget-bundled-content-block-1 block--secondcolumn1--views-block--widget-bundled-content-block-1--5806 block--00609670-cd58-459c-9cfc-dd939a3d58ab block--00609670-cd58-459c-9cfc-dd939a3d58ab--5806 block block-views block-views-blockwidget-bundled-content-block-1> h2>Quick Links/h2> a href# classshow-all>Show all/a> div data-block-uuid00609670-cd58-459c-9cfc-dd939a3d58ab>div classacc-wrap view view-widget-bundled-content view-id-widget_bundled_content view-display-id-block_1 js-view-dom-id-f714c96ad1ea4aa980ecf945bfba743b1ca141548443d70698e8af17cd086edb> div classview-filters> form classviews-exposed-form data-drupal-selectorviews-exposed-form-widget-bundled-content-block-1 action/ methodget idviews-exposed-form-widget-bundled-content-block-1 accept-charsetUTF-8> div classform--inline clearfix> /div>/form> /div> div classview-content> div classview-grouping> div classviews-row > div classviews-field views-field-field-nir-bundle-content>div classfield-content>div classitem-list>ul>li>div class clearfix> div classcontent> div classfield field--name-field-nir-content-ref field--type-entity-reference field--label-hidden field__item> div classfile-link> span classfile file--mime-application-pdf file--application-pdf> a href/static-files/d3bbc008-7e3c-40cd-b4da-c33955a9a0e6 typeapplication/pdf titleBCAB November Corporate Presentation.pdf>Latest Corporate Presentation/a>/span>span classfilesize> 4 MB/span>/div>/div> /div>/div>/li>li>div class clearfix> div classcontent> div classfield field--name-field-nir-content-ref field--type-entity-reference field--label-hidden field__item html-link>a href/news-releases/news-release-details/bioatla-reports-third-quarter-2025-financial-results-and hreflangen>Latest Earnings Release/a>/div> /div>/div>/li>li>div class clearfix> div classcontent> div classfield field--name-field-nir-content-ref field--type-entity-reference field--label-hidden field__item html-link>a href/sec-filings/sec-filing/10-q/0001193125-25-280435 hreflangen>Latest 10-Q/a>/div> /div>/div>/li>li>div class clearfix> div classcontent> div classfield field--name-field-nir-content-ref field--type-entity-reference field--label-hidden field__item html-link>a href/sec-filings/sec-filing/10-k/0000950170-25-046217 hreflangen>Latest 10-K/a>/div> /div>/div>/li>/ul>/div>/div>/div> /div> /div> /div> div classview-footer> /div> /div>/div> /div>/div> /div> /div> div classcolumns large-6 radix-layouts-secondcolumn2 panel-panel> div classpanel-panel-inner> div classblock-region-secondcolumn2>div classblock--home-events block--nir-events__widget block--nir-events__widget--5806 block--secondcolumn2--nir-events__widget block--secondcolumn2--nir-events__widget--5806 block--9fdc82d4-4b55-42df-a5a0-922505cf6c6e block--9fdc82d4-4b55-42df-a5a0-922505cf6c6e--5806 block block-nir-events block-nir-events__widget> div classnir-widget> div classnir-widget--label> Events & Presentations /div> div classnir-widget--content> div classnir-widget--list> div classidm-mb-3 idm-d-flex> div classidm-mr-2> i classfa fa-calendar fa-2x>/i> /div> div> div classh4> div classnir-widget--field nir-widgets--event--title> div classfield-nir-event-title> div classfield__item>a href/events/event-details/bioatla-third-quarter-2025-financial-results-and-business-highlights hreflangen>BioAtla Third Quarter 2025 Financial Results and Business Highlights Conference Call/a>/div> /div> /div> /div> div classnir-widget--field nir-widget--event--date> 11/13/25 at 4:30 PM EST /div> div classnir-widget--field nir-widget--event--webcast> div classfield-nir-event-url> div classfield__item>a hrefhttps://viavid.webcasts.com/starthere.jsp?ei1737355&tp_keyf2ba5b6c52 target_blank>Click here for webcast/a>/div> /div> /div> /div>/div>div classidm-mb-3 idm-d-flex> div classidm-mr-2> i classfa fa-calendar fa-2x>/i> /div> div> div classh4> div classnir-widget--field nir-widgets--event--title> div classfield-nir-event-title> div classfield__item>a href/events/event-details/bioatla-first-quarter-2025-financial-results-and-business-highlights-0 hreflangen>BioAtla Second Quarter 2025 Financial Results and Business Highlights Conference Call/a>/div> /div> /div> /div> div classnir-widget--field nir-widget--event--date> 8/7/25 at 4:30 PM EDT /div> div classnir-widget--field nir-widget--event--webcast> div classfield-nir-event-url> div classfield__item>a hrefhttps://viavid.webcasts.com/starthere.jsp?ei1725409&tp_key937ef0566d target_blank>Click here for webcast/a>/div> /div> /div> /div>/div>div classidm-mb-3 idm-d-flex> div classidm-mr-2> i classfa fa-calendar fa-2x>/i> /div> div> div classh4> div classnir-widget--field nir-widgets--event--title> div classfield-nir-event-title> div classfield__item>a href/events/event-details/citizens-life-sciences-conference hreflangen>Citizens Life Sciences Conference/a>/div> /div> /div> /div> div classnir-widget--field nir-widget--event--date> 5/7/25 at 10:00 AM EDT /div> div classnir-widget--field nir-widget--event--webcast> div classfield-nir-event-url> div classfield__item>a hrefhttps://wsw.com/webcast/jmp65/register.aspx?confjmp65&pagebcab&urlhttps%3A//wsw.com/webcast/jmp65/bcab/1630288 target_blank>Click here for webcast/a>/div> /div> /div> /div>/div> /div> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div>/div> /div> /div> /div> /section> /div>/div>!-- /.sutro-double --> /div>/article> /div>div idblock-nir-pid4199-websitenoticeblock classblock--website-notice-block block--website-notice-block--5806 block--content--website-notice-block block--content--website-notice-block--5806 block--1fdbc8eb-13de-4ea1-9ac5-e4dcd1c0b2bc block--1fdbc8eb-13de-4ea1-9ac5-e4dcd1c0b2bc--5806 block block-nir-website-notices block-website-notice-block> /div> /div> /div> section idstock class> div classrow> div classregion region-stock-feature> div idblock-stockquote data-storage-idnode:5806:flexible_layout classblock--market-data-block__stock-quote block--market-data-block__stock-quote--5806 block--stock-feature--market-data-block__stock-quote block--stock-feature--market-data-block__stock-quote--5806 block--0d2d2ed3-1e54-423c-9398-676324b6743c block--0d2d2ed3-1e54-423c-9398-676324b6743c--5806 block block-nir-market-data-block block-market-data-block__stock-quote> h2 classtext-center no-margin>span classthin>Stock Performance/span>/h2> div classquote-wrapper> h3 classtext-center>span classred-txt> /span> /h3> div classrow text-center> div classmedium-12 columns revealOnScroll-fadeInUp> div classstock-container> div classrow stock-quote data-exchange> div classmedium-6 columns pos_relative> h3>small classthin>Price/small>/br> sup>i classfa fa-arrow-circle->/i>/sup>/h3> /div> div classmedium-6 columns pos_relative> h3>small classthin>Change/small>/br> sup>i classfa fa-arrow-circle->/i>/sup>/h3> /div> /div> /div> /div> /div> /div> /div>div idblock-widgetstockchart classblock--nir-stock-chart block--nir-stock-chart--5806 block--stock-feature--nir-stock-chart block--stock-feature--nir-stock-chart--5806 block--d46aac82-69bf-4f16-ba40-0c73b6a9ce03 block--d46aac82-69bf-4f16-ba40-0c73b6a9ce03--5806 block block-nir-stock-chart row text-center> div classmedium-12 columns revealOnScroll-fadeInUp> div classstock-container> div classstock-graph> img srchttps://api.nasdaqomx.wallst.com/api/chart?displaymountain&symbolBCAB.O-BCAB&scalelinear&duration1dy&frequency15min&gridLineb&bgColorffffff&lineColor666666&fillcolor393a39|393a39&width500&height300&bdr2&volume0 width500 height300 >/img> /div> /div> /div>/div>div idblock-stockinfoattributionthomsonreuters classblock--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--5806 block--stock-feature--attribution-block__stock-info-attribution__thomson-reuters block--stock-feature--attribution-block__stock-info-attribution__thomson-reuters--5806 block--81be58c1-886c-4d3f-aa34-67ebb024d047 block--81be58c1-886c-4d3f-aa34-67ebb024d047--5806 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters row text-center> div classmedium-12 columns revealOnScroll-fadeInUp> div classstock-container> p classattribution-legend> Minimum 15 minutes delayed. Source: LSEG/p> /div> /div>/div> /div> /div> /section> div styledisplay: none; classback-to-top>a classfa fa-chevron-up href# titleBack to top aria-labelBack to top>/a>/div>/div> !-- role main -->footer rolecontentinfo> div classrow footer-sitemap> div classcolumn small-5> img classfooter-logo src/sites/g/files/knoqqb64926/themes/site/nir_pid4199/dist/images/logo-footer.svg altlogo-footer> div classregion region-footer-content> div idblock-gbfootercontent classblock-content--nir-global-block block-content--nir-global-block--6541 block--block-content2bdc849e-d85b-4eab-b947-cc2a5e246798 block--block-content2bdc849e-d85b-4eab-b947-cc2a5e246798--5806 block--footer-content--block-content--2bdc849e-d85b-4eab-b947-cc2a5e246798 block--footer-content--block-content--2bdc849e-d85b-4eab-b947-cc2a5e246798--5806 block--04b9431a-30a1-4483-a7c5-009372dbad64 block--04b9431a-30a1-4483-a7c5-009372dbad64--5806 block block-block-content block-block-content2bdc849e-d85b-4eab-b947-cc2a5e246798> div classfield field--name-field-nir-global-block-node field--type-entity-reference field--label-hidden field__item> div classfield field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item>p classfooter-about>BioAtlasup>®/sup> is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologicssup>™/sup> (CAB) platform exploits the unique microenvironment of diseased tissue to more effectively target cancer./p>/div> /div> /div> /div> /div> div classcolumn small-7> div classrow> div classcol-20> h4 idblock-bioatlafooterlinks-menu>BIOATLA®/h4> ul data-block-uuid8e27ba4c-23af-46bb-8d2e-15631f478bce classfooter-links> li classfooter-link> a hrefhttps://www.bioatla.com/technology/cab/>Technology/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/cab-portfolio/>CAB Portfolio/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/appendix/tumor-microenvironment/>Appendix/a> /li> /ul> /div>div classcol-20> h4 idblock-companymenu-menu>COMPANY/h4> ul data-block-uuid56eba9ca-7123-479c-b9fd-aa9baa649a9f classfooter-links> li classfooter-link> a hrefhttps://www.bioatla.com/about/>About/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/about/#team>Team/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/about/#careers>Careers/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/news/>News/a> /li> /ul> /div>div classcol-20> h4 idblock-legalmenu-menu>LEGAL/h4> ul data-block-uuid5c84c960-0f96-496b-b450-a3e5015e5945 classfooter-links> li classfooter-link> a hrefhttps://www.bioatla.com/privacy-policy/>Privacy Policy/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/site-map/>Site Map/a> /li> li classfooter-link> a hrefhttps://www.bioatla.com/expanded-access-policy/>Expanded Access/a> /li> /ul> /div>div classcol-20> h4 idblock-getintouchmenu-menu>GET IN TOUCH/h4> ul data-block-uuidd28380a3-bbf4-40e6-baab-438e4393d9fc classfooter-links> li classfooter-link> a hrefhttps://www.bioatla.com/contact/>Contact/a> /li> li classfooter-link> span>Corporate Headquarters +1 858-558-0708/span> /li> /ul> /div>div classcol-20> h4 idblock-followusmenu-menu>FOLLOW US/h4> ul data-block-uuid55ecb3f7-9840-48cb-9dd5-999e028d165c classfooter-links> li classfooter-link> a hrefhttps://www.linkedin.com/company/bioatla target_blank classlinkedin>LinkedIn/a> /li> /ul> /div> /div> /div> /div> div classrow> div classmedium-12 columns> ul classmenu> li>Copyright © 2026 BioAtla®, Inc. All rights reserved/li> /ul> /div> /div>/footer> /div> script typetext/javascript>var s_CCSWebHostingAccount trcgbioatla;/script> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node\/5806,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,ajaxPageState:{libraries:eJyVUm1uwyAMvVAUNGl_-nsnmHYAZMBqWcCOsNM2tx-BSluq7ktIYD-ejbEfxWKBIK0avRj66o0Q2KFNsJA_DfQrcS4cGs2BYGNEzyR7SJmTg9JAP2GIysUG0LpcQjGfZqNkKBNqI1iX2E-mvSpqC2ikY01c85yg6J_oYlvub7gZgWxBzzkjVTwy_Zj7ITpu4UDhXzGidX9dWG-lLUljrs0Bs3fb7QzH3svNGOEdrhZCsD6BiIWEReUBr45CkdTKSr52jQj7EOYYnp8OB8NnLCWGXkCrp__d3Pm91pfNfNM11aa2iAs6iYqWuCoCu0DusPF2DgVCvFZdrbyomJ03SB0WZrPpZThHvIhp-5g5LAk_ACUUD_0,theme:nir_pid4199,theme_token:null},ajaxTrustedUrl:{\/investor-relations:true},nir_admin_use_chosen:true,nir_admin_use_select2:false,user:{uid:0,permissionsHash:d708596a53c6f9ea89dcc634506e95c8482222108ef2761dbdcf279cdb37477a}}/script>script srchttps://code.jquery.com/jquery-3.5.1.min.js>/script>script srchttps://code.jquery.com/jquery-migrate-3.3.2.min.js>/script>script src/sites/g/files/knoqqb64926/files/js/js_ImiAzx---TsSr9TXXcq9Zx1Njiahb-gWGfpVdeB2I-s.js?scopefooter&delta2&languageen&themenir_pid4199&includeeJyVUFtqAzEMvFBYE-hPvnOCkgMI2RKJs1prkbVtcvts7EIeFEox2DPjkTxWyQZYUK6eUw3lmQ1IGhkEl5JOm_KncTalZotYuTlcVSJaE9PIlF0NCH1dUbiGB2yWCW1kbwaIomkMv6pD0mnCQv-qqb7un4s697JFPE9rIgyvtN3OeOwfuIMBz3gBJIIkWCugsHkPPGf62O52Qb_YLFNv3V6CdELz8MZ7iv0dHvwquRxbxTfHmp2h6DpN7sN904af8wbmj6p5>/script>script srchttps://assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js crossoriginanonymous async integritysha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf>/script>script src/sites/g/files/knoqqb64926/files/js/js_lkYeVgDPMQJWkurZLhHvRJ8qxs1xc3V4vV8nbm0xc9s.js?scopefooter&delta4&languageen&themenir_pid4199&includeeJyVUFtqAzEMvFBYE-hPvnOCkgMI2RKJs1prkbVtcvts7EIeFEox2DPjkTxWyQZYUK6eUw3lmQ1IGhkEl5JOm_KncTalZotYuTlcVSJaE9PIlF0NCH1dUbiGB2yWCW1kbwaIomkMv6pD0mnCQv-qqb7un4s697JFPE9rIgyvtN3OeOwfuIMBz3gBJIIkWCugsHkPPGf62O52Qb_YLFNv3V6CdELz8MZ7iv0dHvwquRxbxTfHmp2h6DpN7sN904af8wbmj6p5>/script>script src/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v44.0.0>/script>script src/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v1.10.9>/script>script src/sites/g/files/knoqqb64926/files/js/js_Mzl7f2gbHVb4T-hnrhCx8ZTz-6dAwZ29OFeZ8CENKEQ.js?scopefooter&delta7&languageen&themenir_pid4199&includeeJyVUFtqAzEMvFBYE-hPvnOCkgMI2RKJs1prkbVtcvts7EIeFEox2DPjkTxWyQZYUK6eUw3lmQ1IGhkEl5JOm_KncTalZotYuTlcVSJaE9PIlF0NCH1dUbiGB2yWCW1kbwaIomkMv6pD0mnCQv-qqb7un4s697JFPE9rIgyvtN3OeOwfuIMBz3gBJIIkWCugsHkPPGf62O52Qb_YLFNv3V6CdELz8MZ7iv0dHvwquRxbxTfHmp2h6DpN7sN904af8wbmj6p5>/script> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]